These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 7941303)

  • 1. Bovine NK and LAK susceptibility is independent of class I expression on B lymphoblastoid variants.
    Li W; Splitter GA
    Vet Immunol Immunopathol; 1994 Jun; 41(3-4):189-200. PubMed ID: 7941303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
    Falk CS; Noessner E; Weiss EH; Schendel DJ
    Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis.
    Lobo PI; Chang MY; Mellins E
    Immunology; 1996 Aug; 88(4):625-9. PubMed ID: 8881767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells.
    Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK
    Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
    Komatsu F; Kajiwara M
    Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis.
    Chiang EY; Henson M; Stroynowski I
    J Immunol; 2002 Mar; 168(5):2200-11. PubMed ID: 11859106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
    Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
    Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis.
    Chang CS; Brossay L; Kronenberg M; Kane KP
    J Exp Med; 1999 Feb; 189(3):483-91. PubMed ID: 9927510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon--a major regulator of natural killer cell-mediated cytotoxicity.
    Reiter Z
    J Interferon Res; 1993 Aug; 13(4):247-57. PubMed ID: 7693829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
    Gwin JL; Gercel-Taylor C; Taylor DD; Eisenberg B
    J Surg Res; 1996 Jan; 60(1):129-36. PubMed ID: 8592403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
    Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
    Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel role for MHC class II antigens: evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells.
    Lobo PI; Patel HC
    Immunology; 1994 Oct; 83(2):240-4. PubMed ID: 7835941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
    Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
    Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.
    Jabrane-Ferrat N; Calvo F; Faille A; Lagabrielle JF; Boisson N; Quillet A; Fradelizi D
    Br J Cancer; 1990 Apr; 61(4):558-62. PubMed ID: 2109997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.